Complement activation plays a key role in the side‐effects of rituximab treatment von Van Der Kolk, L. E., Grillo‐López, A. J., Baars, J. W., Hack, C. E., Van Oers, M. H. J.

Volltext

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy von VAN DER KOLK, L. E, GRILLO-LOPEZ, A. J, BAARS, J. W, VAN OERS, M. H. J

Volltext

Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils von VAN DER KOLK, L. E, DE HAAS, M, GRILLO-LOPEZ, A. J, BAARS, J. W, VAN OERS, M. H. J

Volltext

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma von MALONEY, D. G, GRILLO-LOPEZ, A. J, BODKIN, D. J, WHITE, C. A, LILES, T.-M, ROYSTON, I, VARNS, C, ROSENBERG, J, LEVY, R

Volltext

ANTIBODY-TARGETED IMMUNOTHERAPY FOR TREATMENT OF MALIGNANCY von White, Christine A, Weaver, Robin L, Grillo-López, Antonio J

Volltext

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma von Piro, L. D., White, C. A., Grillo-López, A. J., Janakiraman, N., Saven, A., Beck, T. M., Varns, C., Shuey, S., Czuczman, M., Lynch, J. W., Kolit, J. E., Jain, V.

Volltext

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma von Berinstein, N. L., Grillo-Lopez, A. J., White, C. A., Bence-Bruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P., Shen, D.

Volltext

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program von P McLaughlin, A J Grillo-López, B K Link, R Levy, M S Czuczman, M E Williams, M R Heyman, I Bence-Bruckler, C A White, F Cabanillas, V Jain, A D Ho, J Lister, K Wey, D Shen, B K Dallaire

Volltext

Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy von CZUCZMAN, M. S, GRILLA-LOPEZ, A. J, WHITE, C. A, SALEH, M, GORDON, L, LOBUGLIO, A. F, JONAS, C, KLIPPENSTEIN, D, DALLAIRE, B, VARNS, C

Volltext

IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma von MALONEY, D. G, GRILLO-LOPEZ, A. J, WEY, K, ROYSTON, I, DAVIS, T, LEVY, R, WHITE, C. A, BODKIN, D, SCHILDER, R. J, NEIDHART, J. A, JANAKIRAMAN, N, FOON, K. A, LILES, T.-M, DALLAIRE, B. K

Volltext

Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab von DAVIS, T. A, WHITE, C. A, DOWDEN, S, LEVY, R, GRILLO-LOPEZ, A. J, VELASQUEZ, W. S, LINK, B, MALONEY, D. G, DILLMAN, R. O, WILLIAMS, M. E, MOHRBACHER, A, WEAVER, R

Volltext

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment von DAVIS, T. A, GRILLO-LOPEZ, A. J, WHITE, C. A, MCLAUGHLIN, P, CZUCZMAN, M. S, LINK, B. K, MALONEY, D. G, WEAVER, R. L, ROSENBERG, J, LEVY, R

Volltext

Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity von Byrd, J. C., White, C. A., Link, B., Lucas, M. S., Velasquez, W. S., Rosenberg, J., Grillo-López, A. J.

Volltext

Response criteria for NHL: Importance of ‘normal’ lymph node size and correlations with response rates von Grillo-López, A. J., Cheson, B. D., Horning, S. J., Peterson, B. A., Carter, W. D., Varns, C. L., Klippenstein, D. L., Shen, C. D.

Volltext

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy von Czuczman, M. S., Grillo-López, A. J., McLaughlin, P., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Rosenberg, J., Alkuzweny, B., Maloney, D.

Volltext

Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity von Byrd, J C, Murphy, T, Howard, R S, Lucas, M S, Goodrich, A, Park, K, Pearson, M, Waselenko, J K, Ling, G, Grever, M R, Grillo-Lopez, A J, Rosenberg, J, Kunkel, L, Flinn, I W

Volltext

Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B-Cell Non-Hodgkin's Lymphoma von WITZIG, T. E, WHITE, C. A, SILVERMAN, D. H. S, PARKER, E, GRILLO-LOPEZ, A. J, WISEMAN, G. A, GORDON, L. I, EMMANOUILIDES, C, RAUBITSCHEK, A, JANAKIRAMAN, N, GUTHEIL, J, SCHILDER, R. J, SPIES, S

Volltext

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program von McLaughlin, P, Grillo-López, A J, Link, B K, Levy, R, Czuczman, M S, Williams, M E, Heyman, M R, Bence-Bruckler, I, White, C A, Cabanillas, F, Jain, V, Ho, A D, Lister, J, Wey, K, Shen, D, Dallaire, B K

Volltext

Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab von Czuczman, M. S., Grillo-López, A. J., Alkuzweny, B., Weaver, R., Larocca, A., Mclaughlin, P.

Volltext

Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up von CZUCZMAN, Myron S, WEAVER, Robin, ALKUZWENY, Baha, BERLFEIN, Judy, GRILLO-LOPEZ, Antonio J

Volltext